Characterization of drug-drug interactions in patients whose substance intake was objectively identified by detection in urine.
Joshua SchreckerBrandi PuetCheryl HildDavid M SchwopePublished in: Expert opinion on drug metabolism & toxicology (2018)
By utilizing a mass spectrometry test to objectively detect recently ingested substances followed by identification of DDIs, healthcare providers may be able to better characterize the true incidence of DDIs. Study findings may not be generalizable to healthcare populations outside of pain management, addiction treatment, and behavioral health.
Keyphrases
- healthcare
- pain management
- mass spectrometry
- physical activity
- end stage renal disease
- ejection fraction
- chronic kidney disease
- public health
- newly diagnosed
- risk factors
- prognostic factors
- liquid chromatography
- health information
- high resolution
- body mass index
- patient reported outcomes
- climate change
- patient reported
- risk assessment
- replacement therapy
- health promotion
- adverse drug
- bioinformatics analysis
- weight loss
- simultaneous determination